Equillium SEC Filings

Equillium, Inc. filed a Form 8-K reporting a letter from independent auditor KPMG LLP dated October 6, 2025. The company states that KPMG reported no disagreements with management on accounting principles, financial statement disclosure, or audit scope, and identified no reportable events as defined under Regulation S‑K. A copy of KPMG's letter is attached as Exhibit 16.1. The filing also notes the Cover Page Interactive Data File is embedded with the Inline XBRL document. The report is signed by Bruce D. Steel, Chief Executive Officer.

Equillium, Inc. has filed a prospectus supplement for an at-the-market offering of shares of its common stock with an aggregate offering price of up to $75,000,000 under its existing Open Market Sale Agreement with LifeSci Capital LLC.

This prospectus supplement updates and expands a prior program that had covered up to $21,950,000 of common stock. Equillium has already sold 1,719,485 shares for aggregate gross proceeds of $0.96 million under the agreement. A legal opinion from Cooley LLP on the validity of the shares is included as an exhibit.

Equillium, Inc. reports an estimated public float of $93.7 million, calculated from 47,085,662 shares held by non-affiliates and a per‑share price of $1.99. The $1.99 price was the highest closing price on The Nasdaq Capital Market within 60 days of this prospectus supplement's filing, specifically on September 11, 2025. The public float figure follows the method in General Instruction I.B.6 of Form S-3 under the Securities Act of 1933.

The company notes this figure is specific to the current filing and that if it later becomes subject to the limitations in General Instruction I.B.6, it will file another supplement to update the ATM prospectus. No other financial results, transactions, or forward-looking statements are provided in this excerpt.

Equillium, Inc. filed a Form S-8 registration statement to register additional shares of common stock for issuance under its 2018 Equity Incentive Plan and 2018 Employee Stock Purchase Plan. The filing relies on General Instruction E, which allows the company to increase the number of securities for existing employee benefit plans by incorporating prior effective S-8 registration statements by reference. The document also lists standard corporate and legal exhibits, including the company’s charter, bylaws, equity plans, legal opinions, auditor consent, and a filing fee table, and is signed by the chief executive officer and the full board of directors.

Equillium, Inc. filed an S-3 shelf registration to register common stock for resale by selling stockholders, including shares issuable upon exercise of pre-funded warrants sold in a recent private placement. The prospectus identifies multiple institutional holders (including Adage, ADAR1 Entities, Coastlands Capital and Janus) and shows specific share counts and warrants subject to beneficial ownership blockers that exclude certain exercisable shares from pre-offering ownership figures. The filing lists exhibits (e.g., merger agreement, charter documents, Registration Rights Agreement dated August 12, 2025 and pre-funded warrant form dated August 11, 2025) and incorporates prior SEC reports by reference. The total filing fee shown aggregates to $81,562.

Equillium, Inc. has regained compliance with Nasdaq’s minimum bid price requirement for its common stock. Nasdaq notified the company on August 29, 2025 that it once again meets Listing Rule 5550(a)(2) for continued inclusion on The Nasdaq Capital Market. Equillium had previously received notices in December 2024 and June 2025 that its shares were below the $1.00 per share bid price requirement, with an additional 180-day grace period granted in June. The company met the rule by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days, a condition that was satisfied on August 28, 2025.

Equillium, Inc. (EQ) reporting person Stephen Connelly, Chief Scientific Officer and Director, received an employee stock option award covering 1,025,000 shares on 08/29/2025 with an exercise price of $1.74. The filing shows the option as acquired (code A) and lists 1,025,000 shares beneficially owned following the transaction. The explanatory note states standard time-based vesting: 25% vest on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Tom Penny, Principal Accounting Officer and director at Equillium, Inc. (EQ), was granted an employee stock option on 08/29/2025. The option permits purchase of 525,000 shares of common stock at an exercise price of $1.74 per share and expires on 08/28/2035. Under the stated vesting schedule, 25% of the option vests on the first anniversary of the vesting commencement date and the remainder vests monthly over the following three years. The shares reported as beneficially owned following the grant are 525,000, held directly by the reporting person.